Notable Runner: Medivation Inc (NASDAQ:MDVN) Institutional Investors Q2 2016 Sentiment

November 29, 2016 - By Dolores Ford   ·   0 Comments

Notable Runner: Medivation Inc (NASDAQ:MDVN) Institutional Investors  Q2 2016 Sentiment

Sentiment for Medivation Inc (NASDAQ:MDVN)

Medivation Inc (NASDAQ:MDVN) institutional sentiment decreased to 0.04 in Q2 2016. Its down -1.17, from 1.21 in 2016Q1. The ratio is negative, as 205 funds increased or started new equity positions, while 170 reduced and sold their equity positions in Medivation Inc. The funds in our partner’s database now own: 141.69 million shares, down from 146.56 million shares in 2016Q1. Also, the number of funds holding Medivation Inc in their top 10 equity positions increased from 9 to 21 for an increase of 12. Sold All: 54 Reduced: 116 Increased: 115 New Position: 90.

Medivation, Inc. is a biopharmaceutical company. The company has a market cap of $13.52 billion. The Firm is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. It currently has negative earnings. The Company, in collaboration with Astellas Pharma, Inc. , has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

It is down 149.05% since February 25, 2016 and is uptrending. It has outperformed by 143.79% the S&P500.

Knoll Capital Management Lp holds 85.95% of its portfolio in Medivation Inc for 4.40 million shares. Consonance Capital Management Lp owns 1.27 million shares or 10.84% of their US portfolio. Moreover, Burren Capital Advisors Ltd has 10.26% invested in the company for 36,400 shares. The New York-based Harvest Management Llc has invested 9.07% in the stock. Ratan Capital Management Lp, a New York-based fund reported 298,101 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 1 insider sale for $155,763 net activity.

Medivation Inc (NASDAQ:MDVN) Ratings Coverage

Ratings analysis reveals 20% of Medivation Inc’s analysts are positive. Out of 20 Wall Street analysts rating Medivation Inc, 4 give it “Buy”, 0 “Sell” rating, while 16 recommend “Hold”. The lowest target is $35 while the high is $166. The stock’s average target of $70.14 is -13.88% below today’s ($81.44) share price. MDVN was included in 48 notes of analysts from July 31, 2015. The firm earned “Buy” rating on Friday, February 19 by Bank of America. The rating was maintained by RBC Capital Markets with “Sector Perform” on Friday, November 6. Brean Capital downgraded the stock to “Hold” rating in Monday, August 22 report. Citigroup downgraded the shares of MDVN in a report on Monday, August 22 to “Neutral” rating. UBS maintained Medivation Inc (NASDAQ:MDVN) on Friday, November 6 with “Buy” rating. Wedbush maintained Medivation Inc (NASDAQ:MDVN) rating on Friday, April 29. Wedbush has “Outperform” rating and $59 price target. Stifel Nicolaus maintained Medivation Inc (NASDAQ:MDVN) rating on Monday, May 2. Stifel Nicolaus has “Buy” rating and $66 price target. The firm has “Overweight” rating given on Monday, March 28 by Barclays Capital. Wedbush downgraded it to “Neutral” rating and $81.50 target price in Monday, August 22 report. The stock of Medivation Inc (NASDAQ:MDVN) earned “Buy” rating by Brean Capital on Monday, August 10.

More notable recent Medivation Inc (NASDAQ:MDVN) news were published by: Latimes.com which released: “Pfizer to pay $14 billion for Medivation, whose drug Xtandi was discovered by UCLA” on August 22, 2016, also Fool.com with their article: “Better Buy: Medivation, Inc. vs. Inovio Pharmaceuticals, Inc.” published on July 12, 2016, Fool.com published: “3 Reasons Medivation, Inc. Stock Could Rise” on March 04, 2016. More interesting news about Medivation Inc (NASDAQ:MDVN) were released by: Fool.com and their article: “Why Medivation, Inc. Shares Crashed 32% in January” published on February 03, 2016 as well as Fool.com‘s news article titled: “Why Medivation, Inc. Jumped 13% in December” with publication date: January 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>